Clinical TrialApr 28, 2026, 07:52 AM
CRDL Expands U.S. MAVERIC Phase III Trial Network
AI Summary
Cardiol Therapeutics Inc. announced the expansion of its U.S. MAVERIC Phase III clinical trial network. This expansion is in response to growing interest in the pivotal program, which is evaluating CardiolRx for the treatment of acute myocarditis. The trial aims to reduce major cardiovascular events in patients with this serious inflammatory heart condition.
Key Highlights
- Cardiol Therapeutics expanded its U.S. MAVERIC Phase III trial network.
- Expansion addresses growing interest in the pivotal program.
- MAVERIC trial evaluates CardiolRx for acute myocarditis.
- The trial aims to reduce major cardiovascular events.
- Acute myocarditis is a serious inflammatory heart condition.
Price Impact
More from CRDL